Overview

Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease

Status:
Unknown status
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find if Etanercept can improve the outcome of ocular lesions of Behcet's Disease treated with Methotrexate and Prednisolone
Phase:
N/A
Details
Lead Sponsor:
Tehran University of Medical Sciences
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Etanercept
Methotrexate
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate